| Through its co-Founder, Dr Paul England, IOTA has considerable experience in high-sensitivity, high-throughput compound screening, both at the biochemical and functional, cell-based level. | | | | IOTA’s main experimental labs are based in the Vrije Universiteit in Amsterdam. Long a centre of excellence for GPCR pharmacology, the University has developed state-of-the-art compound screening facilities, and has the capability of running screens for many different molecular targets in several different formats (fluorescence, NMR, MS, etc). | | |
| |
|
